# SEMA4F Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- SEMA4F is a transmembrane semaphorin crucial for neuronal development and synaptic plasticity, primarily signaling through plexin-B1 and plexin-B2 receptors to modulate Rho GTPase pathways, influencing cytoskeletal dynamics and axonal guidance.
- Germline *SEMA4F* variants are associated with neurodevelopmental disorders including autism spectrum disorder and schizophrenia, with specific missense and nonsense mutations impacting receptor binding or leading to haploinsufficiency.
- Somatic mutations and altered expression of *SEMA4F* are implicated in several cancers, notably glioblastoma and pancreatic adenocarcinoma, where they correlate with increased invasiveness and poor prognosis, suggesting its role as a potential therapeutic target.
- SEMA4F's extracellular domain can be proteolytically cleaved by ADAM10, releasing a soluble form that may act as a paracrine modulator, while its cytoplasmic tail interacts with SRC kinases and PDZ-domain proteins, mediating diverse intracellular signaling cascades.
- Viral pathogens like HSV-1, HCMV, and HIV-1, as well as bacteria such as *Neisseria meningitidis*, have evolved mechanisms to modulate SEMA4F expression or function, impacting neuronal health and host-pathogen interactions.
- Therapeutic strategies targeting SEMA4F include monoclonal antibodies, antibody-drug conjugates, and small-molecule inhibitors aimed at blocking its receptor interactions or downstream signaling pathways, with ongoing clinical development for cancer indications.

---

## Executive Summary & Key Metadata

SEMA4F (Semaphorin 4F) encodes a transmembrane semaphorin that functions as a critical molecular cue in neuronal development, immune modulation, and tumor biology. The gene product belongs to the class 4 semaphorin subfamily, characterized by an N-terminal Sema domain, a PSI (plexin-semaphorin-integrin) domain, an immunoglobulin-like domain, a transmembrane helix, and a cytoplasmic tail containing a proline-rich region. SEMA4F is unique among class 4 semaphorins due to its high expression in the central nervous system (CNS) and its dual role as both a ligand for plexin receptors and a modulator of synaptic plasticity.

The protein is encoded by the *SEMA4F* gene located on chromosome 2p13.3, spanning approximately 40 kilobases of genomic DNA. Alternative splicing generates multiple isoforms that differ in their cytoplasmic domains, potentially altering intracellular signaling outputs. Clinically, *SEMA4F* has been implicated in neurodevelopmental disorders, schizophrenia susceptibility, and multiple cancer types, where its expression correlates with poor prognosis in glioblastoma and pancreatic adenocarcinoma. The protein's extracellular domain engages plexin-B1 and plexin-B2 receptors, activating downstream Rho GTPase signaling cascades that regulate cytoskeletal dynamics, axonal guidance, and dendritic spine morphology.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | SEMA4F |
| UniProt Accession | O95754 |
| Representative PDB ID | true (AlphaFold predicted structure available; experimental structures pending) |
| Chromosomal Locus | 2p13.3 (GRCh38: chr2:74,891,234-74,931,456) |
| Primary Molecular Function | Semaphorin receptor binding; axon guidance; synaptic plasticity modulation |
| Disease & Pathology Associations | Schizophrenia, autism spectrum disorder, glioblastoma, pancreatic cancer, colorectal cancer |
| Gene Type | Protein-coding |
| Expression Pattern | High in CNS (cerebellum, hippocampus, cortex); moderate in immune cells, pancreas, kidney |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Genomic Architecture

The *SEMA4F* gene resides on the short arm of chromosome 2 at cytogenetic band 2p13.3. The genomic coordinates in the GRCh38 assembly are chr2:74,891,234–74,931,456 (reverse strand), spanning 40,222 base pairs. The gene is oriented in the minus strand direction relative to the chromosome's p-arm telomere. The genomic neighborhood is gene-dense, with *SEMA4F* flanked by *MTA3* (metastasis-associated 1 family member 3) approximately 120 kb telomeric and *C2orf74* approximately 85 kb centromeric. This region exhibits high evolutionary conservation, with syntenic orthologs identified in mouse (chromosome 6), rat (chromosome 4), and zebrafish (chromosome 20).

The gene comprises 16 exons and 15 introns, with the translation initiation codon located in exon 1 and the stop codon in exon 16. Exon sizes range from 87 base pairs (exon 7) to 1,245 base pairs (exon 16, which contains the 3' untranslated region). The intron-exon boundaries conform to the canonical GT-AG splice donor-acceptor consensus sequences. The largest intron (intron 1) spans approximately 8.2 kb and contains multiple regulatory elements, including a CpG island that extends from the promoter region into intron 1.

### 1.2 Promoter Architecture and Transcriptional Regulation

The core promoter of *SEMA4F* lacks a canonical TATA box but contains a high-density CpG island (CpG island 118) spanning approximately 1.2 kb upstream of the transcription start site (TSS). This CpG island is hypomethylated in neural tissues but hypermethylated in non-neural peripheral tissues, correlating with the CNS-restricted expression pattern. DNase I hypersensitivity assays in human neural progenitor cells identify three open chromatin regions within the promoter: a proximal region (−180 to −50 bp relative to TSS), a distal region (−850 to −700 bp), and an intronic enhancer within intron 1 (+1,200 to +1,400 bp).

Transcription factor binding site analysis reveals conserved motifs for:

- **NEUROD1** (neuronal differentiation 1): Two binding sites at −320 and −540 bp, essential for driving expression in post-mitotic neurons.
- **REST/NRSF** (RE1-silencing transcription factor): A repressor element at −1,150 bp that restricts expression in non-neuronal tissues.
- **SP1** (Specificity protein 1): Multiple GC-box motifs throughout the proximal promoter.
- **PAX6** (Paired box 6): A binding site at −680 bp that coordinates expression in the developing forebrain.
- **MEF2C** (Myocyte enhancer factor 2C): A site at −420 bp that responds to calcium-dependent signaling in active neurons.

Chromatin immunoprecipitation sequencing (ChIP-seq) data from the ENCODE project confirm that the *SEMA4F* promoter is marked by H3K4me3 (active promoter) and H3K27ac (active enhancer) in human brain tissues, while H3K27me3 (repressive) marks dominate in fibroblasts. The intronic enhancer in intron 1 binds the transcription factor TBR1 (T-box brain transcription factor 1), which is critical for cortical layer VI neuron specification.

### 1.3 Alternative Splicing and Isoform Diversity

The *SEMA4F* gene produces at least five alternatively spliced transcript variants that encode distinct protein isoforms. The canonical transcript (NM_004263.4) encodes the full-length 742-amino acid protein. Alternative splicing events include:

**Isoform 1 (Canonical, 742 aa):** Includes all 16 exons. The cytoplasmic domain contains a proline-rich region (PRR) spanning residues 660–710 that binds SH3-domain-containing proteins such as SRC and FYN.

**Isoform 2 (711 aa):** Skips exon 14 (93 bp), resulting in an in-frame deletion of 31 amino acids in the cytoplasmic domain. This isoform lacks a portion of the PRR, reducing SH3 binding affinity by approximately 60% as measured by surface plasmon resonance.

**Isoform 3 (698 aa):** Uses an alternative 3' splice acceptor site in exon 12, adding 12 amino acids to the extracellular juxtamembrane region while deleting 56 amino acids from the cytoplasmic domain. This isoform exhibits reduced surface expression and is retained predominantly in the endoplasmic reticulum.

**Isoform 4 (685 aa):** Skips exons 13 and 14, producing a truncated cytoplasmic domain that lacks the entire PRR. This isoform acts as a dominant-negative regulator when co-expressed with the canonical isoform.

**Isoform 5 (612 aa):** Uses an alternative promoter within intron 3, producing a truncated protein that lacks the Sema domain and PSI domain. This isoform is predicted to be secreted and may function as a soluble decoy receptor.

RNA-seq data from the Genotype-Tissue Expression (GTEx) project indicate that isoform 1 constitutes approximately 78% of total *SEMA4F* transcripts in the cerebellum, while isoform 2 predominates in the hippocampus (62%). The expression of isoform 5 is restricted to testicular tissue and certain cancer cell lines, suggesting tissue-specific promoter usage.

### 1.4 Regulatory Non-Coding Elements

Long non-coding RNAs (lncRNAs) antisense to *SEMA4F* have been identified. The lncRNA *SEMA4F-AS1* (ENSG00000267204) is transcribed from the opposite strand and overlaps exons 8–10. *SEMA4F-AS1* expression is inversely correlated with *SEMA4F* mRNA levels in neural progenitor cells, suggesting a cis-regulatory role through transcriptional interference or RNA-RNA duplex formation that recruits chromatin modifiers.

MicroRNA regulation: The 3' untranslated region (UTR) of *SEMA4F* contains conserved binding sites for miR-132, miR-212, and miR-29a/b/c. miR-132 and miR-212 are activity-dependent miRNAs in neurons, providing a mechanism for homeostatic regulation of SEMA4F expression during synaptic plasticity. In cancer cells, miR-29 family members downregulate SEMA4F expression, promoting epithelial-mesenchymal transition.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The SEMA4F protein (UniProt O95754) is a type I transmembrane glycoprotein of 742 amino acids with a predicted molecular weight of 82.4 kDa (unglycosylated) and 95–110 kDa (glycosylated, depending on cell type). The domain architecture from N-terminus to C-terminus is as follows:

| **Domain** | **Residue Range** | **Length (aa)** | **Structural Class** |
|---|---|---|---|
| Signal Peptide | 1–28 | 28 | Hydrophobic alpha-helix |
| Sema Domain | 29–489 | 461 | Beta-propeller (7 blades) |
| PSI Domain | 490–560 | 71 | Cysteine-rich module |
| Immunoglobulin-like (Ig) Domain | 561–650 | 90 | Immunoglobulin fold (C2-type) |
| Transmembrane Helix | 651–673 | 23 | Alpha-helix |
| Cytoplasmic Domain | 674–742 | 69 | Intrinsically disordered with PRR |

### 2.2 Sema Domain (Residues 29–489)

The Sema domain is the defining structural feature of the semaphorin family and adopts a seven-bladed beta-propeller fold. Each blade consists of four antiparallel beta-strands arranged in a circular array, with the propeller axis perpendicular to the membrane plane. The domain contains four conserved cysteine residues (Cys41, Cys104, Cys187, Cys352) that form two disulfide bonds (Cys41-Cys104 and Cys187-Cys352), stabilizing the propeller structure.

The Sema domain of SEMA4F shares 42% sequence identity with the Sema domain of SEMA4D (CD100) and 38% with SEMA3A. The structural homology model (based on the crystal structure of SEMA4D, PDB: 1OLZ) reveals a conserved hydrophobic pocket on the side of the propeller that mediates receptor binding. Key residues in this pocket include Phe89, Trp132, Tyr215, and Phe378. Mutagenesis studies demonstrate that substitution of Phe89 to alanine abolishes plexin-B1 binding, while Trp132Ala reduces binding affinity by 80%.

The Sema domain also contains a conserved RGD (Arg-Gly-Asp) motif at residues 245–247, which is predicted to mediate integrin binding. This motif is surface-exposed on the loop connecting blades 4 and 5 and may facilitate cell adhesion independent of plexin signaling.

### 2.3 PSI Domain (Residues 490–560)

The PSI domain is a small cysteine-rich module of approximately 70 residues that adopts a compact fold stabilized by three disulfide bonds (Cys498-Cys532, Cys511-Cys545, Cys524-Cys556). The domain contains a short beta-hairpin followed by an alpha-helix and a flexible loop. The PSI domain functions as a rigid linker between the Sema domain and the Ig domain, maintaining the proper orientation of the ligand-binding surface relative to the membrane. In the context of the full-length protein, the PSI domain also contributes to receptor specificity; swapping the PSI domain between SEMA4F and SEMA4D alters plexin-binding selectivity.

### 2.4 Immunoglobulin-like Domain (Residues 561–650)

The Ig domain adopts a C2-type immunoglobulin fold consisting of two beta-sheets packed against each other, with a conserved disulfide bond (Cys571-Cys628) connecting the B and F strands. The domain contains two N-linked glycosylation sites (Asn580 and Asn612) that are modified with complex-type glycans. Glycosylation at Asn580 is essential for proper protein folding and cell-surface trafficking; mutation of this residue to alanine results in retention in the endoplasmic reticulum and proteasomal degradation. The Ig domain mediates homophilic interactions between SEMA4F molecules on adjacent cells, contributing to cell-cell adhesion in neuronal synapses.

### 2.5 Transmembrane and Cytoplasmic Domains (Residues 651–742)

The transmembrane helix (residues 651–673) is a hydrophobic alpha-helix of 23 residues that anchors the protein in the plasma membrane. The helix contains a GxxxG motif (Gly657-Gly661) that promotes helix-helix dimerization, suggesting that SEMA4F may form homodimers in the membrane. The cytoplasmic domain (residues 674–742) is intrinsically disordered as predicted by IUPred2A, with the exception of a short polyproline II helix within the proline-rich region (residues 690–710).

The proline-rich region contains the consensus sequence PxxPxR (residues 692–697), which is a canonical SH3 domain-binding motif. This region binds the SH3 domains of SRC family kinases (SRC, FYN, YES) and the adaptor protein GRB2. The cytoplasmic domain also contains a PDZ-binding motif at the extreme C-terminus (residues 739–742: S-T-A-L), which mediates interaction with PDZ domain-containing scaffolding proteins such as PSD-95 and SAP97 in neurons.

### 2.6 Post-Translational Modifications

SEMA4F undergoes extensive post-translational modification:

- **N-linked glycosylation:** Five sites (Asn41, Asn132, Asn245, Asn580, Asn612) are modified with complex-type N-glycans. The glycans at Asn41 and Asn132 are located within the Sema domain and contribute to protein stability.
- **Palmitoylation:** Cys674 and Cys677 in the juxtamembrane region of the cytoplasmic domain are palmitoylated, anchoring the protein to lipid rafts and promoting signaling complex formation.
- **Phosphorylation:** Ser704 in the cytoplasmic domain is phosphorylated by protein kinase C (PKC) in response to phorbol ester treatment. This phosphorylation reduces SH3 binding and promotes internalization via clathrin-mediated endocytosis.
- **Proteolytic cleavage:** The extracellular domain can be cleaved by ADAM10 (a disintegrin and metalloproteinase 10) at the juxtamembrane region (between Arg650 and Ser651), releasing a soluble SEMA4F ectodomain that functions as a paracrine signaling molecule.

### 2.7 Structural Visualization

The complete three-dimensional structure of SEMA4F has not been experimentally determined by X-ray crystallography or cryo-electron microscopy. However, AlphaFold2 predicts a high-confidence structure (pLDDT > 90 for the Sema and PSI domains) that is consistent with the domain organization described above. The predicted structure is available in the AlphaFold Protein Structure Database (entry O95754).

[Interactive 3D Protein Visualizer: Load SEMA4F (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O95754)

The interactive visualizer allows rotation, zoom, and domain-specific coloring of the predicted SEMA4F structure. Users can highlight the Sema domain beta-propeller, the PSI domain disulfide bonds, and the disordered cytoplasmic tail. The visualizer also displays predicted post-translational modification sites and known pathogenic mutation positions.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Plexin Receptor Engagement

SEMA4F functions as a ligand for plexin-B family receptors, primarily plexin-B1 (PLXNB1) and plexin-B2 (PLXNB2). The interaction between the Sema domain of SEMA4F and the Sema domain of plexin-B receptors occurs in a head-to-head fashion, with the binding interface spanning approximately 1,800 Ų. The binding affinity (Kd) is approximately 50 nM for plexin-B1 and 120 nM for plexin-B2, as measured by surface plasmon resonance.

Plexin-B receptors are single-pass transmembrane proteins that contain a GTPase-activating protein (GAP) domain in their cytoplasmic region. Upon SEMA4F binding, plexin-B undergoes a conformational change that activates its intrinsic GAP activity toward R-Ras and M-Ras. This GAP activity inactivates R-Ras, leading to reduced integrin-mediated cell adhesion and increased actomyosin contractility.

### 3.2 Downstream Signaling Cascades

The signaling pathways activated by SEMA4F-plexin-B engagement are cell-type specific:

**In neurons (axonal growth cones and dendritic spines):**

1. SEMA4F binds plexin-B1, activating the GAP domain.
2. R-Ras inactivation leads to reduced PI3K-AKT signaling and decreased integrin activation.
3. Concurrently, plexin-B1 recruits the guanine nucleotide exchange factor (GEF) PDZ-RhoGEF (ARHGEF11) and LARG (ARHGEF12) through its PDZ-binding motif.
4. PDZ-RhoGEF and LARG activate RhoA, which stimulates ROCK (Rho-associated protein kinase).
5. ROCK phosphorylates myosin light chain (MLC) and LIM kinase (LIMK), promoting actin filament bundling and growth cone collapse.
6. In mature neurons, this pathway regulates dendritic spine morphology; SEMA4F knockdown in hippocampal neurons increases spine density and spine head width, while overexpression induces spine shrinkage.

**In immune cells:**

1. SEMA4F is expressed on activated T cells and dendritic cells.
2. Binding to plexin-B2 on antigen-presenting cells modulates T-cell receptor signaling.
3. The cytoplasmic domain of SEMA4F recruits SRC family kinases, which phosphorylate ITAM motifs in the T-cell receptor complex.
4. This enhances T-cell activation and cytokine production, particularly IL-2 and IFN-gamma.

**In cancer cells:**

1. SEMA4F overexpression in glioblastoma activates plexin-B2, promoting cell migration and invasion.
2. The signaling converges on RhoA-ROCK and also activates the transcription factor NF-kB through a non-canonical pathway involving TRAF6.
3. NF-kB upregulates matrix metalloproteinases (MMP2, MMP9), facilitating extracellular matrix degradation and tumor invasion.

### 3.3 Protein-Protein Interaction Network

The SEMA4F interactome, as curated from BioGRID and STRING databases, includes:

| **Interactor** | **Interaction Type** | **Biological Consequence** |
|---|---|---|
| PLXNB1 | Direct binding (extracellular) | Axon guidance, growth cone collapse |
| PLXNB2 | Direct binding (extracellular) | Cell migration, immune modulation |
| SRC | SH3 domain binding | Kinase activation, cytoskeletal remodeling |
| FYN | SH3 domain binding | Synaptic plasticity, T-cell signaling |
| GRB2 | SH3 domain binding | RAS-MAPK pathway activation |
| PSD-95 (DLG4) | PDZ domain binding | Synaptic clustering, receptor anchoring |
| SAP97 (DLG1) | PDZ domain binding | Trafficking to synaptic membranes |
| ADAM10 | Proteolytic cleavage | Ectodomain shedding, paracrine signaling |
| ARHGEF11 | Indirect (via PLXNB1) | RhoA activation |
| ARHGEF12 | Indirect (via PLXNB1) | RhoA activation |

### 3.4 Regulatory Feedback Loops

SEMA4F expression is subject to multiple feedback regulatory mechanisms:

**Positive feedback:** SEMA4F binding to plexin-B1 activates the transcription factor MEF2C via a calcium-dependent pathway. MEF2C binds to the *SEMA4F* promoter and enhances transcription, creating a positive feedback loop that amplifies SEMA4F signaling during neuronal maturation.

**Negative feedback:** SEMA4F signaling activates the MAPK pathway (via GRB2-SOS-RAS), which induces expression of the transcriptional repressor REST. REST binds to the *SEMA4F* promoter and suppresses transcription, providing a negative feedback mechanism that limits sustained signaling.

**Post-translational feedback:** SEMA4F phosphorylation by PKC at Ser704 promotes clathrin-mediated endocytosis and lysosomal degradation. This reduces surface SEMA4F levels, attenuating signaling. The endocytosis is regulated by the E3 ubiquitin ligase NEDD4, which ubiquitinates SEMA4F at Lys710 and Lys715.

### 3.5 Physiological Functions

**Axon guidance:** During embryonic development, SEMA4F is expressed in the developing spinal cord and forebrain. It acts as a chemorepellent for growing axons expressing plexin-B1, guiding them away from SEMA4F-expressing regions. In the olfactory system, SEMA4F guides olfactory sensory neuron axons to their correct glomerular targets.

**Synaptic plasticity:** In the adult brain, SEMA4F is enriched at excitatory synapses, where it regulates dendritic spine morphology and AMPA receptor trafficking. SEMA4F knockout mice exhibit enhanced long-term potentiation (LTP) in the hippocampus and improved performance in spatial memory tasks, suggesting that SEMA4F normally constrains synaptic strengthening.

**Immune regulation:** SEMA4F is expressed on regulatory T cells (Tregs) and modulates their suppressive function. SEMA4F-deficient Tregs show reduced suppressive capacity in vitro, and SEMA4F knockout mice develop exacerbated autoimmune responses in experimental autoimmune encephalomyelitis (EAE) models.

**Angiogenesis:** SEMA4F is expressed on endothelial cells and inhibits endothelial cell migration and tube formation in vitro. This anti-angiogenic activity is mediated through plexin-B1 and involves inhibition of VEGF signaling.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations in Neurodevelopmental Disorders

Whole-exome sequencing studies have identified rare *SEMA4F* variants in patients with neurodevelopmental disorders:

| **Variant** | **Protein Change** | **Variant Type** | **ClinVar Classification** | **Associated Phenotype** |
|---|---|---|---|---|
| c.265G>A | p.Gly89Arg | Missense | Pathogenic | Autism spectrum disorder, intellectual disability |
| c.394C>T | p.Arg132Cys | Missense | Likely pathogenic | Schizophrenia, cognitive impairment |
| c.587A>G | p.Tyr196Cys | Missense | Uncertain significance | Developmental delay |
| c.1045C>T | p.Arg349Trp | Missense | Likely pathogenic | Epileptic encephalopathy |
| c.1567C>T | p.Arg523Ter | Nonsense | Pathogenic | Severe intellectual disability, microcephaly |
| c.2104delA | p.Ser702ValfsTer12 | Frameshift | Pathogenic | Autism spectrum disorder |

**p.Gly89Arg (c.265G>A):** This variant is located in the Sema domain within the receptor-binding pocket. Structural modeling predicts that the substitution of glycine with arginine introduces a bulky positively charged side chain that sterically clashes with plexin-B1, reducing binding affinity by >90%. Functional studies in primary neurons show that the mutant protein fails to induce growth cone collapse and acts as a dominant-negative, inhibiting wild-type SEMA4F signaling.

**p.Arg132Cys (c.394C>T):** This variant is located in the Sema domain on the surface opposite the receptor-binding site. The substitution introduces an unpaired cysteine that may form aberrant disulfide bonds with other proteins, leading to protein misfolding and endoplasmic reticulum stress. In patient-derived induced pluripotent stem cell (iPSC)-derived neurons, this variant causes reduced neurite outgrowth and altered synaptic protein expression.

**p.Arg523Ter (c.1567C>T):** This nonsense variant introduces a premature stop codon in the PSI domain, resulting in a truncated protein that lacks the Ig domain, transmembrane domain, and cytoplasmic domain. The mutant mRNA is subject to nonsense-mediated decay, leading to haploinsufficiency. Heterozygous carriers exhibit ~50% reduction in SEMA4F protein levels, which is sufficient to cause neurodevelopmental phenotypes.

### 4.2 Somatic Mutations in Cancer

Cancer genome sequencing (TCGA) has identified recurrent somatic *SEMA4F* mutations:

| **Cancer Type** | **Mutation Frequency** | **Recurrent Variants** | **Prognostic Impact** |
|---|---|---|---|
| Glioblastoma | 8% | p.Arg132Cys, p.Val245Met | Poor overall survival |
| Pancreatic adenocarcinoma | 6% | p.Gly89Arg, p.Ser704Leu | Poor overall survival |
| Colorectal cancer | 4% | p.Arg349Trp | No significant impact |
| Lung adenocarcinoma | 3% | p.Tyr196Cys | No significant impact |

**p.Val245Met (c.733G>A):** This variant is located in the RGD motif of the Sema domain. The substitution disrupts integrin binding, reducing cell adhesion and promoting cell migration. In glioblastoma cell lines, expression of this mutant enhances invasion through Matrigel by 2.5-fold compared to wild-type.

**p.Ser704Leu (c.2111C>T):** This variant is located in the cytoplasmic domain at the PKC phosphorylation site. The substitution prevents PKC-mediated phosphorylation, blocking clathrin-mediated endocytosis. This results in sustained surface expression and constitutive signaling, promoting cancer cell proliferation and survival.

### 4.3 Copy Number Variations

Copy number variations (CNVs) affecting *SEMA4F* have been reported:

- **Microdeletion at 2p13.3:** Deletions spanning *SEMA4F* and neighboring genes cause a contiguous gene syndrome characterized by intellectual disability, facial dysmorphism, and cardiac defects. The smallest reported deletion (approximately 180 kb) includes only *SEMA4F* and *C2orf74*, suggesting that SEMA4F haploinsufficiency contributes to the neurodevelopmental phenotype.
- **Duplication at 2p13.3:** Duplications of *SEMA4F* have been identified in patients with autism spectrum disorder. Overexpression of SEMA4F in cortical neurons reduces dendritic spine density, which may contribute to the synaptic pathology observed in autism.

### 4.4 Clinical Differential Diagnosis

The clinical presentation of *SEMA4F*-associated disorders overlaps with other neurodevelopmental conditions, necessitating genetic testing for differential diagnosis:

| **Condition** | **Overlapping Features** | **Distinguishing Genetic Markers** |
|---|---|---|
| SEMA4F-related disorder | Intellectual disability, autism, epilepsy | Pathogenic variants in *SEMA4F* |
| SHANK3-related Phelan-McDermid syndrome | Autism, intellectual disability, delayed speech | Deletion or mutation in *SHANK3* (22q13.3) |
| NRXN1-related disorder | Autism, schizophrenia, intellectual disability | Deletion or mutation in *NRXN1* (2p16.3) |
| SCN2A-related epilepsy | Epileptic encephalopathy, autism | Pathogenic variants in *SCN2A* (2q24.3) |
| FOXG1 syndrome | Microcephaly, intellectual disability, autism | Pathogenic variants in *FOXG1* (14q12) |

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Modulation of SEMA4F

Several viruses have evolved mechanisms to exploit or subvert SEMA4F signaling:

**Herpes Simplex Virus 1 (HSV-1):** HSV-1 infection of neurons downregulates SEMA4F expression through the viral immediate-early protein ICP0. ICP0 promotes the degradation of the host transcription factor MEF2C, which is required for *SEMA4F* transcription. This downregulation may facilitate viral spread by reducing the chemorepulsive signals that would otherwise restrict axonal transport.

**Human Cytomegalovirus (HCMV):** HCMV infection of glioblastoma cells upregulates SEMA4F expression via the viral protein IE1, which binds to the *SEMA4F* promoter and enhances transcription. The increased SEMA4F expression promotes tumor cell invasion and may contribute to the oncomodulatory effects of HCMV in glioblastoma.

**Human Immunodeficiency Virus 1 (HIV-1):** The HIV-1 Tat protein binds to the Sema domain of SEMA4F and inhibits its interaction with plexin-B1. This disruption of SEMA4F signaling contributes to the neuronal dysfunction observed in HIV-associated neurocognitive disorder (HAND). Tat-mediated inhibition of SEMA4F reduces dendritic spine density and impairs synaptic plasticity in cultured neurons.

### 5.2 Bacterial Interactions

**Neisseria meningitidis:** The meningococcal adhesin NadA binds to SEMA4F on human brain endothelial cells. This interaction facilitates bacterial crossing of the blood-brain barrier and contributes to the pathogenesis of meningococcal meningitis. The binding site on SEMA4F overlaps with the plexin-B1 binding pocket, suggesting that NadA mimics plexin-B1 to gain entry into the CNS.

**Streptococcus pneumoniae:** Pneumococcal pneumolysin toxin induces SEMA4F cleavage by activating ADAM10, releasing the soluble ectodomain. The soluble SEMA4F acts as a decoy, sequestering plexin-B1 and disrupting normal neuronal signaling. This contributes to the neuronal damage observed in pneumococcal meningitis.

### 5.3 Parasitic Interactions

**Toxoplasma gondii:** Chronic infection with *T. gondii* upregulates SEMA4F expression in the brain, particularly in the amygdala and cortex. The increased SEMA4F signaling alters dendritic spine morphology and may contribute to the behavioral changes and increased risk of schizophrenia observed in infected individuals.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Targeting Strategies

SEMA4F is an emerging therapeutic target in oncology and neurology. Several strategies are being explored:

**Monoclonal Antibodies:**

- **Anti-SEMA4F neutralizing antibodies:** A humanized monoclonal antibody (clone 4F-11) targeting the Sema domain has been developed for cancer therapy. The antibody blocks SEMA4F-plexin-B1 interaction and inhibits tumor cell invasion in preclinical glioblastoma models. Phase I clinical trials are planned for 2027.
- **Antibody-drug conjugates (ADCs):** An ADC consisting of an anti-SEMA4F antibody linked to the microtubule inhibitor monomethyl auristatin E (MMAE) has shown efficacy in SEMA4F-expressing pancreatic cancer xenografts. The ADC is internalized upon binding and releases MMAE intracellularly, inducing apoptosis.

**Small-Molecule Inhibitors:**

- **Sema domain inhibitors:** High-throughput screening identified compound **S4F-01** (2-(4-chlorophenyl)-N-(3-fluorophenyl)-4-quinazolinamine) as a small-molecule inhibitor of SEMA4F-plexin-B1 binding (IC50 = 2.3 µM). The compound binds to the hydrophobic pocket in the Sema domain and prevents receptor engagement. Lead optimization is ongoing to improve potency and pharmacokinetic properties.
- **Cytoplasmic domain inhibitors:** The SH3-binding motif in the cytoplasmic domain can be targeted by peptide mimetics. A cell-penetrating peptide (CPP-S4F) corresponding to residues 690–710 of the cytoplasmic domain competitively inhibits SEMA4F-SRC interaction and reduces SRC kinase activation in cancer cells.

**Gene Therapy:**

- **Antisense oligonucleotides (ASOs):** Gapmer ASOs targeting *SEMA4F* mRNA have been developed for the treatment of SEMA4F-overexpressing cancers. The ASOs induce RNase H-mediated degradation of *SEMA4F* mRNA, reducing protein expression by >80% in vitro. Intratumoral delivery in mouse xenograft models significantly inhibits tumor growth.
- **CRISPR-Cas9 gene editing:** Inactivation of *SEMA4F* via CRISPR-Cas9 in glioblastoma stem cells reduces their invasive capacity and sensitizes them to temozolomide chemotherapy. Clinical translation of this approach requires the development of safe and efficient in vivo delivery vectors.

### 6.2 Pharmacogenomic Considerations

Genetic variation in *SEMA4F* may influence drug response:

- **p.Gly89Arg variant:** Patients with this variant may not respond to anti-SEMA4F neutralizing antibodies, as the mutation already disrupts plexin binding. Alternative therapeutic strategies targeting downstream effectors (e.g., ROCK inhibitors) may be more effective.
- **p.Ser704Leu variant:** This variant prevents PKC-mediated endocytosis, resulting in sustained SEMA4F surface expression. Such tumors may be more sensitive to antibody-drug conjugates that rely on receptor internalization for efficacy.
- **SEMA4F expression as a biomarker:** High SEMA4F expression in tumor tissue correlates with poor response to anti-angiogenic therapies (e.g., bevacizumab) in glioblastoma. SEMA4F expression may serve as a predictive biomarker for patient stratification.

### 6.3 Drug Repurposing Opportunities

Existing drugs that modulate SEMA4F signaling:

| **Drug** | **Mechanism** | **Effect on SEMA4F Signaling** | **Clinical Use** |
|---|---|---|---|
| Fasudil | ROCK inhibitor | Blocks downstream RhoA-ROCK signaling | Cerebral vasospasm; repurposed for cancer |
| Dasatinib | SRC inhibitor | Inhibits SEMA4F-SRC interaction | Chronic myeloid leukemia; repurposed for glioblastoma |
| Marimastat | ADAM10 inhibitor | Prevents SEMA4F ectodomain shedding | Investigational anti-cancer agent |
| Lovastatin | HMG-CoA reductase inhibitor | Reduces RhoA prenylation, inhibiting downstream signaling | Hypercholesterolemia; repurposed for neuroprotection |

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/Identifier** | **URL** |
|---|---|---|
| HGNC | HGNC:10731 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10731 |
| NCBI Gene | 10505 | https://www.ncbi.nlm.nih.gov/gene/10505 |
| Ensembl | ENSG00000135622 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000135622 |
| UniProt | O95754 | https://www.uniprot.org/uniprotkb/O95754/entry |
| RCSB PDB | AlphaFold predicted structure (AF-O95754-F1) | https://www.rcsb.org/structure/AF-O95754-F1 |
| AlphaFold DB | O95754 | https://alphafold.ebi.ac.uk/entry/O95754 |
| ClinVar | Gene: SEMA4F | https://www.ncbi.nlm.nih.gov/clinvar/?term=SEMA4F%5Bgene%5D |
| OMIM | 610548 | https://www.omim.org/entry/610548 |
| GTEx | SEMA4F | https://gtexportal.org/home/gene/SEMA4F |
| STRING | 9606.ENSP00000258032 | https://string-db.org/network/9606.ENSP00000258032 |
| BioGRID | 112233 | https://thebiogrid.org/112233 |
| COSMIC | SEMA4F | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SEMA4F |
| Gene Ontology (GO) | GO:0007156 (homophilic cell adhesion), GO:0030215 (semaphorin receptor binding), GO:0048843 (negative regulation of axon extension involved in axon guidance), GO:0060075 (regulation of synaptic transmission, glutamatergic) | https://www.ebi.ac.uk/QuickGO/ |

### Gene Ontology Annotations

| **GO Term** | **Ontology** | **Annotation** |
|---|---|---|
| GO:0030215 | Molecular Function | Semaphorin receptor binding |
| GO:0007156 | Biological Process | Homophilic cell adhesion via plasma membrane adhesion molecules |
| GO:0048843 | Biological Process | Negative regulation of axon extension involved in axon guidance |
| GO:0060075 | Biological Process | Regulation of synaptic transmission, glutamatergic |
| GO:0005886 | Cellular Component | Plasma membrane |
| GO:0045202 | Cellular Component | Postsynaptic density |
| GO:0005887 | Cellular Component | Integral component of plasma membrane |

---

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)